Press Release Archive

10.28.2012

Pfizer Reschedules Issuance Of Third Quarter 2012 Performance Report And Associated Conference Call And Webcast to November 1, 2012 Due To Expected Severe Weather Conditions

10.25.2012

Pfizer Declares A 22-Cent Fourth-Quarter 2012 Dividend

10.24.2012

Pfizer’s XALKORI® Receives Conditional Marketing Authorization from the European Commission for the Treatment of Adults with Previously Treated ALK-Positive Advanced Non-Small Cell Lung Cancer in the EU

10.21.2012

Pfizer To Acquire NextWave Pharmaceuticals, Inc.

10.17.2012

Pfizer Consumer Healthcare Responds to PHS II Findings with Statement and Centrum® Silver® Multivitamin B-roll and Photo Assets

10.16.2012

Pfizer Announces Top-line Results From Phase 3 Trial Of INLYTA® (axitinib) In Treatment-Naïve Patients With Advanced Renal Cell Carcinoma

10.15.2012

New Study With CHANTIX®/CHAMPIX® (varenicline) Tablets Suggests Favorable Benefit-Risk Profile In Adult Smokers With Major Depressive Disorder

10.10.2012

Pfizer Announces Top-Line Results From A Phase 3 Long-Term Safety Study Of ALO-02:

10.09.2012

New Report Reveals Programs That Promote Healthy Ageing Can Help Reduce Rising Health Costs1

10.03.2012

Pfizer Announces Top-Line Results Of Prevenar 13® Phase 3 Trial In Adults 18 To 49 Years Of Age

10.01.2012

ELIQUIS® (apixaban) Demonstrates Consistent Reductions in Stroke and Systemic Embolism, Major Bleeding and Mortality Compared to Warfarin in Patients with Nonvalvular Atrial Fibrillation at Varying Risk for Stroke and Bleeding

09.26.2012

FDA Acknowledges Receipt of Resubmission of the ELIQUIS® (apixaban) New Drug Application to Reduce the Risk of Stroke and Systemic Embolism in Patients with Nonvalvular Atrial Fibrillation